For further proving these bioinformatic findings based on TCGA, we then performed a series of validation experiments (Figs. 7 and 8) and the results were in agreement with previous TCGA findings that SPTBN1 expression had negative and positive relationships with TNFSF9 expression in KIRC and UVM, respectively, further suggesting its potential to be a novel biomarker for anti-cancer therapies and prognosis in KIRC and UVM. This evidence concerns the gene SPTBN1 and cancer.